CompanyACIUNasdaq1015 Lausanne, V8

AC Immune SA

AC Immune develops active immunotherapies and small molecules targeting misfolded proteins in neurodegenerative diseases.

SEC EDGAR ClinicalTrials.gov acimmune.com

6-KSep 23Latest SEC filing, period to Sep 23

Sep 23Latest story

September 2026

AC Immune reports positive week-100 safety and immunogenicity data for ACI-7104 in Parkinson's trial

Sep 23Clinical readoutAC Immune SA

August 2026

AC Immune reports positive early Phase 1 data for NLRP3 inhibitor ACI-19764

Aug 20Clinical readoutAC Immune SA

AC Immune wins FDA Fast Track and IND clearance for Parkinson's candidate ACI-7104

Aug 11Regulatory milestoneAC Immune SA

June 2026

AC Immune reports 12-month interim data from ABATE trial of ACI-24

Jun 30Clinical readoutAC Immune SA